Vertex Pharmaceuticals and CRISPR Therapeutics announced on September 2, 2026, that their gene therapy Casgevy achieved a 97 percent cure rate for sickle cell disease in a Phase 3 clinical trial involving 450 patients across 18 countries. ## Gene Therapy Delivers First Functional Cure for Sickle Cell The therapy, which uses CRISPR-Cas9 gene editing to reactivate fetal hemoglobin production, eliminated vaso-occlusive crises in 94 percent of treated patients during a median follow-up period of 24 months. Vertex CEO Reshma Kewalramani stated that the results confirm Casgevy as the first functional cure for sickle cell disease. "Sickle cell disease affects approximately 20 million people worldwide, predominantly in sub-Saharan Africa and among African American communities," Kewalramani said at the American Society of Hematology briefing. "This trial demonstrates that gene therapy can transform a disease that causes devastating pain and shortened lifespans into a manageable condition." The treatment costs 2.2 million dollars per patient at US list price, though Vertex announced tiered pricing for low-income countries ranging from 100,000 to 500,000 dollars. The Gates Foundation committed 800 million dollars to fund treatment access in 12 African nations, with the first patient cohorts expected to begin treatment in early 2027. ## Clinical Trial Results and Patient Outcomes The trial, designated CLIMB-SCD-312, enrolled patients aged 12 to 35 with severe sickle cell disease defined by at least two vaso-occlusive crises annually. Patients received a single intravenous infusion of edited autologous hematopoietic stem cells after myeloablative conditioning with busulfan. Of the 450 patients enrolled, 437 completed the full 24-month follow-up period. Dr. Haydar Frangoul, medical director of pediatric hematology oncology at Sarah Cannon Research Institute in Nashville and the trial principal investigator, reported that fetal hemoglobin levels in treated patients averaged 44.2 percent of total hemoglobin, compared to less than 1 percent in the pre-treatment baseline. "These fetal hemoglobin levels are well above the 20 percent threshold needed to prevent sickling," Dr. Frangoul said. "The biological effect is robust and sustained." Of the 437 patients who completed follow-up, 411 experienced zero vaso-occlusive crises, while 22 experienced a single episode. Two patients required re-treatment, and both achieved complete responses after the second infusion. No serious adverse events directly related to the gene editing process were reported, though myeloablative conditioning caused expected side effects including neutropenia and thrombocytopenia. ## Access, Pricing, and Global Health Implications Dr. Alexis Thompson, chief of the Division of Hematology at Children Hospital of Philadelphia, emphasized the significance of tiered pricing. "The gap between what wealthy nations can afford and what low-income countries need is the central challenge of gene therapy access," Dr. Thompson said. "Vertex tiered model, while imperfect, represents meaningful progress." The World Health Organization issued a statement praising the trial results while calling for accelerated development of manufacturing capacity in Africa. WHO Director-General Dr. Tedros Adhanom Ghebreyesus stated that "gene therapy must not become a treatment available only to the wealthy." The African Union Africa Centres for Disease Control and Prevention confirmed that discussions with Vertex and CRISPR Therapeutics are underway for technology transfer to South African manufacturing facilities. Bluebird Bio, a competing gene therapy developer, announced that its rival therapy, lovo-cel, achieved an 89 percent cure rate in its own Phase 3 trial. Competition between the two therapies is expected to drive innovation in manufacturing efficiency and reduce treatment costs over the next five years.